Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.54 |
| ▸ | POLA1 | P09884 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6281591 | 0.88 | KCNH2 (0.57) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6282421 | 0.87 | TDP1 (0.43) | MEN1KMT2ARXFP1 | |
| SCHEMBL6281183 | 0.83 | KCNH2 (0.71) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6281221 | 0.81 | KCNH2 (0.61) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6285022 | 0.81 | KCNH2 (0.57) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6282424 | 0.80 | KCNH2 (0.58) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6283579 | 0.80 | KCNH2 (0.62) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6283657 | 0.79 | ALDH1A1 (0.54) | KCNH2MEN1KMT2AALDH1A1 | |
| SCHEMBL6278020 | 0.77 | KCNH2 (0.59) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6286648 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6878705-B2 | 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents | PFIZER (US) | 2005-04-12 | — | — | US | claimed |
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-12-23 | — | — | US | claimed |
| EP-1465895-A2 | 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-13 | — | — | EP | claimed |
| WO-2003059911-A2 | 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | claimed |
| US-6878705-B2 | 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents | PFIZER (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259907-A1 | 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS | IL4, ZC3HAV1, IRF3 | KCNH2 484/4885POLA1 533/4885MEN1 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.